{"url_path":"/sec/bold/8-k/2026-06-23/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","accession_number":"0001193125-26-278570","cik":"0001782303","ticker":"BOLD","issuer_name":"Boundless Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","primary_entity_key":"0001782303","primary_entity_name":"Boundless Bio, Inc."},"word_count":156,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 23, 2026, Boundless Bio and Serapha issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nOn June 23, 2026, Boundless Bio and Serapha released a pre-recorded call featuring representatives from both companies discussing the Contemplated Transactions. The pre-recorded call can be accessed by visiting www.boundlessbio.com. Furnished as Exhibit 99.2 hereto is the transcript of the pre-recorded call.\n\n \n\nThe information in this Item 7.01, including Exhibits 99.1, and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing."}